The National Evaluation System for health Technology Coordinating Center’s early "Test-Cases" have been successful in answering some important questions about what works and what doesn’t with real-world evidence for medical devices, organizers say. Much more of that is planned in the coming months leading up to the launch of active surveillance activities later this year. Market Pathways spoke to key NESTcc leaders and participants as they prep for the effort’s next phase.Read Article
30 Years of Experience
A frequent contributor to MedTech Strategist and Market Pathways, Mark Ratner specializes in personalized medicine, molecular diagnostics, oncology, and neurology. He is an editorial adviser and frequent contributor to Nature Biotechnology, where he began his career in biotech in 1988 as a news editor. For most of the 1990s, Mark worked for and consulted to biotech companies in the Boston area.